HUMA News and Press, Humacyte Inc. From 05/12/25

2025-05-12 14:29:36 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) ...

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, Ma...

2025-05-08 18:48:18 ET Humacyte, Inc. (HUMA) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 7.18%. The average open to low on the day of earnings was -7.37%. The average open to close o...

2025-05-08 18:43:19 ET Humacyte, Inc. (HUMA) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in HUMA stock price following earnings has averaged ±2.41% , with a median of 2.29%. The s...

2025-03-28 14:48:37 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) ...

2025-03-28 13:48:49 ET Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call March 27, 2025, 08:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason - President and CEO Dale Sander - CFO and Chief...

2025-03-28 07:44:18 ET More on Humacyte Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) Humacyte: Upside Potential, But I Will Wait For Revenue Trends ...

- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first commercial sales of Symvess - - Budget Impact Model for Symvess published i...

Entera Bio Ltd. (ENTX) is expected to report $-0.08 for Q4 2024 Audacy, Inc. (AUDAQ) is expected to report for quarter end 2024-12-31 The Dixie Group Inc. (DXYN) is expected to report for quarter end 2024-12-31 POET Technologies Inc. (POET) is expected to report $-0.09 for Q4 2024 ...

2025-03-27 12:55:20 ET More on Humacyte Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) Humacyte: Upside Potential, But I Will Wait For Revenue Trends ...